Oneview Healthcare Chess Depository Interests repr 1 earnings date
Want to see AU:ONE full AI Analyst Report?
Oneview Healthcare Chess Depository Interests repr 1 (ONE) Q2 2026 Earnings Report
AU:ONE Q2 2026 EPS Results
- Actual EPS
- -AUD 0.02
- Consensus EPS
- -AUD 0.01
- Beat/Miss
- Missed by -AUD 0.01
- One Year Ago EPS
- -AUD 0.02
AU:ONE Q2 2026 Revenue Results
- Actual Revenue
- AUD 9.11M
- Expected Revenue
- AUD 12.09M
- Beat/Miss
- Missed by -AUD 2.98M
- YoY Revenue Growth
- -16.59%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/26/2026
- Time
- After Close
- Conference Call
- Wednesday, August 26, 2026
Oneview Healthcare Chess Depository Interests repr 1's next earnings date is estimated for February 19, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call presents a predominantly positive operational and strategic picture despite headline revenue decline. Key strengths include significant recurring revenue growth (20% constant currency), a marked gross margin improvement (61% to 70%), reduced cash burn (‑15% YoY), a strengthened balance sheet via a $19m placement (pro‑forma EUR 11.4m), and meaningful commercial and product momentum — notably certification and pipeline from Epic's Bedside Hub and an expanded Baxter partnership. Principal negatives are the 14% reported revenue decline driven by currency effects and lower nonrecurring revenue, delayed endpoint deployments (notably the Children’s Hospital of Ireland) and competitive pricing pressures in Australia. On balance, strategic initiatives (Bedside Hub, Baxter, new front end, Ovie, AI productivity) and improved unit economics appear to outweigh near‑term revenue/currency headwinds.
Management guided to reach cash‑flow breakeven in the near term, driven by continued recurring‑revenue growth (H1 recurring revenue +13% reported, +20% constant currency; recurring now 79% of total revenue vs 60% a year ago), margin improvement (gross margin +9pp to 70% from 61%, gross profit €3.8m) and tighter cost control (cash OpEx -6% YoY, operating cash outflow -15% vs H1 2025, EBITDA loss €4.0m, an 11% improvement). They highlighted a pro‑forma cash position of €11.4m (cash €7.2m at 30 June plus the expected $7m/≈€4.2m tranche), a live endpoint base of ~15,000, a pipeline of 16 Bedside Hub opportunities representing >20,000 beds, 4 logos in late negotiation and a target to win another 3–4 Bedside Hub logos by year‑end; management also flagged meaningful ARR upside from these deals (new U.S. endpoints ~60% higher recurring revenue than recent Australian decommissions). Operational levers include product launches (new front end, Bedside Hub), AI efficiency gains (85% of code AI‑assisted, ~+170% feature velocity), observed renewal price increases of 15–20%, and further headcount/cost efficiencies (spend down ~10% since H2 2024) to support scalable growth.
- Strong Recurring Revenue Growth (Constant Currency)Recurring revenue grew 13% year‑over‑year on a reported basis and 20% on a constant currency basis, driven by new endpoint deployments and price increases; recurring revenue now represents 79% of total revenue (up from 60% a year ago).
- Material Gross Margin ExpansionGross margin increased from 61% to 70% (a 9 percentage‑point improvement), helping keep gross profit stable at EUR 3.8m despite a 14% decline in total reported revenue.
- Improved Profitability Trends and Lower Cash BurnOperating EBITDA loss improved by 11% year‑over‑year to an EBITDA loss of EUR 4.0m; operating cash outflow (cash burn) declined 15% versus H1 2025. Cash operating expenses fell 6% year‑over‑year following the mid‑2025 restructuring.
- Balance Sheet Strengthened via PlacementCompleted a $19m placement in March 2026 (Tranche 1: $12m received; Tranche 2: $7m subject to shareholder approval). Cash at 30 June was EUR 7.2m and pro‑forma cash including Tranche 2 is approx. EUR 11.4m, providing runway to execute growth priorities.
- New High‑Potential Revenue Channel with Epic (Bedside Hub)Bedside Hub certified with Epic in May and launched as a new, lower‑price tier channel. Epic exposure has generated a pipeline of 16 opportunities representing over 20,000 beds (exceeding current deployments) and an upcoming 15‑bed enterprise pilot with a top‑20 U.S. health system.
- Strategic Commercial Partnership Momentum (Baxter)Added to Baxter's National Care Communication agreement with a top‑10 U.S. health system; Baxter partnership expected to deliver material funnel activity with benefits anticipated to flow through from Q4.
- Product & Innovation Progress — Front End, Ovie, DataLaunched Bedside Hub; new front end substantially complete and being deployed to first two customers; Ovie agentic intelligence layer and a major real‑time data/analytics upgrade in place to support care orchestration and clinician insights.
- AI‑Driven Development Productivity GainsAI adoption across the software development lifecycle: ~85% of code authored by AI agents with human supervision, feature delivery velocity increased ~170% (story points), and faster bug root‑cause identification driving higher quality and speed to value.
- Demonstrated Pricing PowerSecured price increases on renewals in the U.S. with examples of 15%–20% uplifts, indicating improved pricing leverage for the recurring revenue stack.
AU:ONE Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 19, 2027 | 2026 (Q4) | 0.00- | -0.01 | ― | ― |
| Aug 26, 2026 | 2026 (Q2) | -0.01-0.02 | -0.02 | 0.00% (+0.00) | |
| Feb 11, 2026 | 2025 (Q4) | -0.01-0.01 | -0.01 | 33.33% (+0.00) | |
| Aug 12, 2025 | 2025 (Q2) | -0.01-0.02 | -0.02 | 0.00% (+0.00) | |
| Feb 25, 2025 | 2024 (Q4) | -0.01-0.01 | -0.02 | 18.18% (+0.00) | |
| Aug 29, 2024 | 2024 (Q2) | -0.01-0.02 | -0.02 | 0.00% (+0.00) | |
| Feb 27, 2024 | 2023 (Q4) | -0.01-0.01 | -0.01 | 0.00% (+0.00) | |
| Aug 28, 2023 | 2023 (Q2) | -0.02-0.02 | -0.02 | 0.00% (+0.00) | |
| Feb 23, 2023 | 2022 (Q4) | -0.01-0.02 | -0.02 | 21.43% (+0.00) | |
| Aug 29, 2022 | 2022 (Q2) | -0.01-0.02 | -0.03 | 37.50% (+0.01) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


